Drug Profile
B 5626
Alternative Names: B5626; Neksol PMLatest Information Update: 22 Jul 2016
Price :
$50
*
At a glance
- Originator Samyang Biopharmaceuticals Corporation
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Breast cancer; Lung cancer
Most Recent Events
- 31 Jul 2006 Clinical trials in Breast cancer in South Korea (Parenteral) before July 2006
- 31 Jul 2006 Clinical trials in Lung cancer in South Korea (Parenteral) before July 2006
- 31 Jul 2006 Launched for Breast cancer in South Korea (Parenteral)